Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC -0.67%70 Equity-to-Asset is 0.26 as of Jun. 2026, which is 4% below its 10-year median of 0.27. GuruFocus rates PAHC with a GF Score™ of 70/100 and a GF Value™ of $31.34 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Phibro Animal Health ranks worse than 85.1% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Phibro Animal Health's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $385 Mil. Phibro Animal Health's Total Assets for the quarter that ended in Jun. 2026 was $1,501 Mil.
Therefore, Phibro Animal Health's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.26.
The historical rank and industry rank for Phibro Animal Health's Equity-to-Asset or its related term are showing as below:
PAHC'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21 Med: 0.27 Max: 0.3
Current: 0.26
During the past 13 years, the highest Equity to Asset Ratio of Phibro Animal Health was 0.30. The lowest was 0.21. And the median was 0.27.
PAHC's Equity-to-Asset is ranked worse than 85.1% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs PAHC: 0.26
Phibro Animal Health (NAS:PAHC) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Phibro Animal Health Equity-to-Asset Related Terms
Phibro Animal Health Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Phibro Animal Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PAHC vs XERS, HROW, ANIP: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Phibro Animal Health's Equity to Asset Ratio for the fiscal year that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phibro Animal Health (PAHC) has a Equity-to-Asset of 0.26 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Phibro Animal Health and its competitors. This is near median its historical median of 0.27. Over the past decade, Phibro Animal Health's Equity-to-Asset has ranged from 0.21 to 0.30. According to the industry distribution chart, Phibro Animal Health ranks #857 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 85.1%.
Is Phibro Animal Health's Equity-to-Asset too high?
Phibro Animal Health's current Equity-to-Asset of 0.26 is near median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 0.30. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Phibro Animal Health's value of 0.26 is 56.7% below this industry median. Based on the distribution chart, Phibro Animal Health ranks #857 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Phibro Animal Health has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's Equity-to-Asset compare to XERS and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #857 out of 1007 companies for Equity-to-Asset. This places Phibro Animal Health in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Phibro Animal Health's value of 0.26 is 56.7% below this benchmark. Historically, Phibro Animal Health's own Equity-to-Asset has ranged from 0.21 to 0.30 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 0.60, Phibro Animal Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current Equity-to-Asset of 0.26 is 56.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current Equity-to-Asset is 0.26, which is near median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $31.34, compared to a current price of $38.33 — trading 22.3% above its estimated fair value. The current Equity-to-Asset is 0.26, which is near median its 10-year median of 0.27 and 56.7% below the Drug Manufacturers industry median of 0.60. Phibro Animal Health's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current Equity-to-Asset is 0.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $38.33 is trading 22.3% above its estimated GF Value™ of $31.34.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
Equity-to-Asset: 0.26 (near median its 10-year median of 0.27)
GF Value™: $31.34 vs. price of $38.33 (22.3% above fair value)
Industry Position: 56.7% below the Drug Manufacturers median (#857 of 1007)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
70GF Score
Get the complete analysis for PAHC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
